Betulinic acid and its derivatives: A patent review (2008-2013)

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 8, 2014, Pages 913-923

  Csuk, René ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Antitumor activity; Betulinic acid; Cancer; Cytotoxicity

Indexed keywords

BETULIC ACID; LIPOSOME; TERPENOID DERIVATIVE; TRITERPENE; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; CYTOTOXICITY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG SOLUBILITY; HUMAN; LIPOSOMAL DELIVERY; NANOEMULSION; NEOPLASM; NONHUMAN; PATENT; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; STRUCTURE ACTIVITY RELATION; TUMOR CELL; APOPTOSIS; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; NEOPLASMS; PATHOLOGY; SOLUBILITY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG DESIGN; HUMANS; NEOPLASMS; PATENTS AS TOPIC; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TRITERPENES;

EID: 84904635038     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.927441     Document Type: Review

References (131)

1. Laszczyk MN. Pentacyclic triterpenes of the lupane, oleanane and ursane group as tools in cancer therapy. Planta Med 2009;75:1549-60
2. Gheorgheosu D, Duicu O, Dehelean C, et al. Betulinic acid as a potent and complex antitumor phytochemical: a minireview. Anticancer Agents Med Chem 2014; doi: 10.2174/1871520614666140223192148
3. Petronelli A, Pannitteri G, Testa U. Triterpenoids as new promising anticancer drugs. Anticancer Drug 2009;20:880-92
4. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003;66:1022-37
5. Fulda S. Modulation of apoptosis by natural products for cancer therapy. Planta Med 2010;76:1075-9
6. Khazir J, Mir BA, Mir SA, et al. Natural products as lead compounds in drug discovery. J Asian Nat Prod Res 2013;15:764-88
7. Sisodiya PS. Plant derived anticancer agents: a review. Int J Res Dev Pharm Life Sci 2013;2:293-308
8. Dzubak P, Hajduch M, Vydra D, et al. Pharmacological activities of natural triterpenoids and their therapeutic implications. Nat Prod Rep 2006;23:394-411
9. Bhui K, Srivastava AK, Shukla Y. Cytotoxic action of natural pentacyclic triterpenes on cancer cells: lupane-type compounds. In: Salvador JAR, editor. Pentacyclic triterpenes as promising agents in cancer. Nova Science Publishers, Inc, Hauppauge, NY, USA; 2010. p. 49-87
10. Dehelean CA, Feflea S, Ganta S, et al. Anti-angiogenic effects of betulinic acid administered in nanoemulsion formulation using chorioallantoic membrane assay. J Biomed Nanotechnol 2011;7:317-24
11. Shin J, Lee HJ, Jung D-B, et al. Suppression of STAT3 and HIF-1 alpha mediates anti-angiogenic activity of betulinic acid in hypoxic PC-3 prostate cancer cells. PLoS ONE 2011;6:e21492
12. Kim SJ, Quan HY, Jeong KJ, et al. Beneficial effect of betulinic acid on hyperglycemia via suppression of hepatic glucose production. J Agric Food Chem 2014;62:434-42
13. Birken GmbH. Scheffler A. Triterpene-containing oleogels use for wound-healing. WO2011064271A2; 2011
14. Moghaddam MG, Ghaffari AFBH. Various botanical sources of betulinic acid: a review. Asian J Chem 2012;24:4843-6
15. Parra A, Rivas F, Garcia-Granados A, et al. Microbial transformation of triterpenoids. Mini-Rev Org Chem 2009;6:307-20
16. Barthel A, Stark S, Csuk R. Oxidative transformations of betulinol. Tetrahedron 2008;64:9225-9
17. Csuk R, Schmuck K, Schäfer R. A practical synthesis of betulinic acid. Tetrahedron Lett 2006;47:8769-70
18. Krasutsky PA. Birch bark research development. Nat Prod Res 2006;23:919-42
19. Li J, Zhang Y. Increase of betulinic acid production in Saccharomyces cerevisiae by balancing fatty acids and betulinic acid forming pathways. Appl Microbiol Biotechnol 2014;doi: 10.1007/s00253-013-5461-1
20. Vib Vzw, Belg; Universiteit Gent. Goossens A, Moses T, Pollier J, et al. Triterpenoid sapogenin production by recombinant plant and microbial cultures. WO2013167751A1; 2013
21. Feng Y, Li M, Liu J, et al. A novel one-step microbial transformation of betulin to betulinic acid catalysed by Cunninghamella blakesleeana. Food Chem 2013;136:73-9
22. Traubenberg IK. Betulin. III. Zh Russ Fiz-Khim O-va 1917;49:381-94
23. Trumbull ER, Bianchi E, Eckert DJ, et al. Tumor inhibitory agents from Vauquelinia corymbosa (Rosaceae). J Pharm Sci 1976;65:1407-8
24. Yasukawa K, Takido M, Matsumoto T, et al. Sterol and triterpene derivatives from plants inhibit the effects of a tumor promoter, and sitosterol and betulinic acid inhibit tumor-formation in mouse skin 2-stage carcinogenesis. Oncology 1991;48:72-6
25. Pisha E, Chai H, Lee IS, et al. Discovery of betulinic acid as a selective inhibitor of human-melanoma that functions by induction of apoptosis. Nat Med 1995;1:1046-51
26. Saelens X, Festjens N, Vande Walle L, et al. Toxic proteins released from mitochondria in cell death. Oncogene 2004;23:2861-74
27. Patlolla JMR, Rao CV. Triterpenoids for cancer prevention and treatment: current status and future prospects. Curr Pharm Biotechnol 2012;13:147-55
28. Fulda S. Betulinic acid for cancer treatment and prevention. Int J Mol Sci 2008;9:1096-107
29. Zuco V, Supino R, Righetti SC, et al. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett 2002;175:17-25
30. Eder-Czembirek C, Erovic BM, Czembirek C, et al. Betulinic acid a radiosensitizer in head and neck squamous cell carcinoma cell lines. Strahlenther Onkol 2010;186:143-8
31. Zschornak MP, Passin S, Kessler J, et al. Effects of betulinic acid and irradiation on malignant glioma cells under normal and hypoxic conditions. Exp Strahlenther Klin Strahlenbiol 2011;20:59-63
32. Zhao Z, Wang J, Tang J, et al. JNK-and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells. Biochem J 2012;444:291-301
33. Aisha AFA, Abu-Salah KM, Ismail Z, et al. Alpha-Mangostin enhances betulinic acid cytotoxicity and inhibits cisplatin cytotoxicity on HCT 116 colorectal carcinoma cells. Molecules 2012;17:2939-54
34. Gao Y, Jia Z, Kong X, et al. Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res 2011;71:5182-93
35. Wachsberger PR, Burd R, Wahl ML, et al. Betulinic acid sensitization of low pH adapted human melanoma cells to hyperthermia. Int J Hyperthermia 2002;18:153-64
36. Li Q, Li Y, Wang X, et al. Co-treatment with ginsenoside Rh2 and betulinic acid synergistically induces apoptosis in human cancer cells in association with enhanced capsase-8 activation, bax translocation, and cytochrome c release. Mol Carcinog 2011;50:760-9
37. Eichenmueller M, Hemmerlein B, von Schweinitz D, et al. Betulinic acid induces apoptosis and inhibits hedgehog signalling in rhabdomyosarcoma. Br J Cancer 2010;103:43-51
38. Schmidt ML, Kuzmanoff KL, Ling-Indeck L, et al. Betulinic acid induces apoptosis in human neuroblastoma cell lines. Eur J Cancer 1997;33:2007-10
39. Fulda S, Friesen C, Los M, et al. Betulinic acid triggers CD95 (APO-1/Fas)-and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 1997;57:4956-64
40. Fulda S, Friesen C, Los M, et al. CD95 (APO-1/Fas)-and p53-independent apoptosis by betulinic acid involves mitochondrial alterations and activation of caspases. Blood 1997;90:2207
41. Tan YM, Yu R, Pezzuto JM. Betulinic acid-induced programmed cell death in human melanoma cells involves mitogen-activated protein kinase activation. Clin Cancer Res 2003;9:2866-75
42. Li Y, He K, Huang Y, et al. Betulin induces mitochondrial cytochrome c release associated apoptosis in human cancer cells. Mol Carcinog 2010;49:630-40
43. Gao M, Lau PM, Kong SK. Mitochondrial toxin betulinic acid induces in vitro eryptosis in human red blood cells through membrane permeabilization. Arch Toxicol 2014;88:755-68
44. Broniatowski M, Flasinski M, Wydro P. Investigation of the interactions of lupane type pentacyclic triterpenes with outer leaflet membrane phospholipids-Langmuir monolayer and synchrotron X-ray scattering study. J Colloid Interface Sci 2012;381:116-24
45. Yadav VR, Prasad S, Sung B, et al. Targeting inflammatory pathways by triterpenoids for prevention and treatment of cancer. Toxins (Basel) 2010;2:2428-66
46. Parrondo R, de las Pozas A, Reiner T, et al. NF-kappaB activation enhances cell death by antimitotic drugs in human prostate cancer cells. Mol Cancer 2010;9:182-doi: 10.1186/1476-4598-9-182
47. Hsu T-I, Wang M-C, Chen S-Y, et al. Betulinic acid decreases specificity protein 1 (Sp1) level via increasing the sumoylation of Sp1 to inhibit lung cancer growth. Mol Pharmacol 2012;82:1115-28
48. Killinger B, Shah M, Moszczynska A. Co-administration of betulinic acid and methamphetamine causes toxicity to dopaminergic and serotonergic nerve terminals in the striatum of late adolescent rats. J Neurochem 2014;128:764-75
49. Dang Z, Huang L, Chen CH. HIV-1 maturation inhibitors: an update. Drug Future 2009;34:797-802
50. Lee KH. Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach. J Nat Prod 2010;73:500-16
51. Blazevski J, Petkovic F, Momcilovic M, et al. Betulinic acid regulates generation of neuroinflammatory mediators responsible for tissue destruction in multiple sclerosis in vitro. Acta Pharmacol Sin 2013;34:424-31
52. Karna E, Szoka L, Palka JA. Betulinic acid inhibits the expression of hypoxia-inducible factor 1a and vascular endothelial growth factor in human endometrial adenocarcinoma cells. Mol Cell Biochem 2010;340:15-20
53. Chintharlapalli S, Papineni S, Lei P, et al. Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and-independent downregulation of specificity proteins (Sp) transcription factors. BMC Cancer 2011;11:371
54. Mertens-Talcott SU, Noratto GD, Li X, et al. Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: role of Sp transcription factors and microRNA-27a:ZBTB10. Mol Carcinog 2013;52:591-602
55. Karna E, Palka JA. Mechanism of betulinic acid inhibition of collagen biosynthesis in human endometrial adenocarcinoma cells. Neoplasma 2009;56:361-6
56. Mukherjee R, Jaggi M, Siddiqui MJA, et al. Synthesis and cytotoxic activity of 3-O-acyl/3-hydrazine/2-bromo/20, 29-dibromo betulinic acid derivatives. Bioorg Med Chem Lett 2004;14:4087-91
57. Univerzita Karlova v Praze, Prirodovedecka Fakulta, Czech Rep.; Univerzita Palackeho v Olomouci. Sarek J, Biedermann D, Hajduch M. Triterpenoid derivatives for treating tumor diseases and pharmaceutical composition in which the derivatives are comprised. CZ301158B6; 2009
58. Spivak AY, Nedopekina DA, Shakurova ER, et al. Synthesis of lupane triterpenoids with triphenylphosphonium substituents and studies of their antitumor activity. Russ Chem Bull 2013;62:188-98
59. Casaroli-Marano R, Gallego-Pinazo R, Fernandez-Blanco CT, et al. Age-related macular degeneration: clinical findings following treatment with antiangiogenic drugs. J. Ophthal. 2014.2014:346360
60. Bar FMA, Khanfar MA, Elnagar AY, et al. Rational design and semisynthesis of betulinic acid analogues as potent topoisomerase inhibitors. J Nat Prod 2009;72:1643-50
61. Eiznhamer DA, Xu ZQ. Betulinic acid: a promising anticancer candidate. IDrugs 2004;7:359-73
62. Tripathi L, Kumar P, Singh R. A review on extraction, synthesis and anticancer activity of betulinic acid. Curr Bioact Compd 2009;5:160-8
63. Chen J-J, Patel A, Sodani K, et al. BBA, a synthetic derivative of 23-hydroxybutulinic acid, reverses multidrug resistance by inhibiting the efflux activity of MRP7 (ABCC10). PLoS One 2013;8:e74573
64. Kommera H, Kaluderovic GN, Kalbitz J, et al. Small structural changes of pentacyclic lupane type triterpenoid derivatives lead to significant differences in their anticancer properties. Eur J Med Chem 2010;45:3346-53
65. Reyes-Zurita FJ, Pachon-Pena G, Lizarraga D, et al. The natural triterpene maslinic acid induces apoptosis in HT29 colon cancer cells by a JNK-p53-dependent mechanism. BMC Cancer 2011;11:154
66. Sankpal UT, Goodison S, Abdelrahim M, et al. Targeting SP1 transcription factor in prostate cancer therapy. Med Chem 2011;7:518-25
67. Santos RC, Salvador JAR, Cortes R, et al. New betulinic acid derivatives induce potent and selective antiproliferative activity through cell cycle arrest at the S phase and caspase dependent apoptosis in human cancer cells. Biochimie 2011;93:1065-75
68. Sawada N, Kataoka K, Kondo K, et al. Betulinic acid augments the inhibitory effects of vincristine on growth and lung metastasis of B16F10 melanoma cells in mice. Br J Cancer 2004;90:1672-8
69. Sun Y-F, Song C-K, Viernstein H, et al. Apoptosis of human breast cancer cells induced by microencapsulated betulinic acid from sour jujube fruits through the mitochondria transduction pathway. Food Chem 2013;138:1998-2007
70. Yamai H, Sawada N, Yoshida T, et al. Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo. Int J Cancer 2009;125:952-60
71. Kommera H, Kaluderovic GN, Bette M, et al. In vitro anticancer studies of alpha-and beta-d-glucopyranose betulin anomers. Chem-Biol Interact 2010;185:128-36
72. Gheorgheosu D, Jung M, Oren B, et al. Betulinic acid suppresses NGAL-induced epithelial-to-mesenchymal transition in melanoma. Biol Chem 2013;394:773-81
73. Park SY, Kim HJ, Kim KR, et al. Betulinic acid, a bioactive pentacyclic triterpenoid, inhibits skeletal-related events induced by breast cancer bone metastases and treatment. Toxicol Appl Pharmacol 2014;275:152-62
74. Xu Y-P, Yang M, Pan DH, et al. Preparation of 131I-betulinic acid and its biodistribution in murine model of hepatocellular tumor. J Radioanal Nucl Chem 2011;288:157-61
75. Thibeault D, Gauthier C, Legault J, et al. Synthesis and structure-activity relationship study of cytotoxic germanicane-and lupane-type 3 beta-O-monodesmosidic saponins starting from betulin. Bioorg Med Chem 2007;15:6144-57
76. Gauthier C, Legault J, Piochon-Gauthier M, et al. Advances in the synthesis and pharmacological activity of lupane-type triterpenoid saponins. Phytochem Rev 2011;10:521-44
77. Hung HY, Nakagawa-Goto K, Tokuda H, et al. A-ring modified betulinic acid derivatives as potent cancer preventive agents. Bioorg Med Chem Lett 2014;24:1005-8
78. AdaBio Co., Ltd. Hiraishi K, Jimma F, Soma H, et al. Aqueous solutions of pentacyclic triterpene acids and manufacture thereof using galacturonic acid or glucuronic acid as solubilizer. JP2013227284A; 2013
79. Hetero Research Foundation. Parthasaradhi Reddy B, Manohar Sharma V, Rathnakar Reddy K, et al. Pharmaceutically acceptable salts of novel betulinic acid derivatives. WO2012095705A1; 2012
80. Universitatea de Medicina si Farmacie "Victor Babes" Timisoara. Borcan F, Soica C, Serban F, et al. Polyether-urethane carrier for transdermal transport of pharmaceutical compounds used in stomatology. RO128801A0; 2013
81. Hertrampf A, Gruendemann C, Jaeger S, et al. In vitro cytotoxicity of cyclodextrin-bonded birch bark extract. Planta Med 2012;78:881-9
82. University of Utah Research Foundation. Rapoport NY, Nam KH. Stable nanoemulsions for ultrasound-mediated drug delivery and imaging. US20110177005A1; 2011
83. Fujifilm Corp. Arakawa J, Kanazawa K, Suzuki K, et al. Aqueous dispersion containing pentacyclic triterpene and lecithin, and method for producing same. WO2013065416A1; 2013
84. Univerzita Karlova v Praze, Prirodovedecka Fakulta, Czech Rep.; Univerzita Palackeho v Olomouci. Sarek J, Hajduch M, Svoboda M, et al. Method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, a soluble formulation of a pentacyclic or tetracyclic terpenoid and a pharmaceutical composition containing this soluble formulation. WO2008037226A2; 2008
85. Thibeault D, Gauthier C, Legault J, et al. Synthesis and cytotoxicity of lupane-type triterpenoid glyceryl esters. Bioorg Med Chem Lett 2012;22:4735-9
86. Suresh C, Zhao H, Gumbs A, et al. New ionic derivatives of betulinic acid as highly potent anti-cancer agents. Bioorg Med Chem Lett 2012;22:1734-8
87. Biedermann D, Eigenrova B, Hajduch M, et al. Synthesis and evaluation of biological activity of the quaternary ammonium salts of lupane-, oleanane-, and ursane-type acids. Synthesis 2010;2010:3839-48
88. Mullauer FB, van Bloois L, Daalhuisen JB, et al. Betulinic acid delivered in liposomes reduces growth of human lung and colon cancers in mice without causing systemic toxicity. Anticancer Drug 2011;22:223-33
89. Univerzita Palackeho v Olomouci, Czech Rep.; Institute of Organic Chemistry, Polish Academy of Sciences; Bio Apex S. R.O. Pakulski ZA, Cmoch P, Oklestkova J, et al. Preparation of saccharide lupane derivatives, their use as anticancer agents. WO2009094958A1; 2009
90. Gauthier C, Legault J, Lavoie S, et al. Synthesis and Cytotoxicity of Bidesmosidic Betulin and Betulinic Acid Saponins. J Nat Prod 2009;72:72-81
91. Gauthier C, Legault J, Piochon M, et al. Synthesis, cytotoxicity, and haemolytic activity of chacotrioside lupane-type neosaponins and their germanicane-type rearrangement products. Bioorg Med Chem Lett 2009;19:2310-14
92. Goff RD, Thorson JS. Enhancing the Divergent Activities of Betulinic Acid via Neoglycosylation. Org Lett 2009;11:461-4
93. Cmoch P, Pakulski Z, Swaczynova J, Strnad M. Synthesis of lupane-type saponins bearing mannosyl and 3, 6-branched trimannosyl residues and their evaluation as anticancer agents. Carbohydr Res 2008;343:995-1003
94. Nguyen XN, Nguyen HT, Kiem PV, et al. Lupane triterpene glycosides from leaves of Acanthopanax koreanum and their cytotoxic activity. Chem Pharm Bull 2009;57:986-9
95. Gauthier C, Legault J, Lavoie S, et al. Synthesis of two natural betulinic acid saponins containing alpha-L-rhamnopyranosyl-(1 → 2)-alpha-L-arabinopyranose and their analogues. Tetrahedron 2008;64:7386-99
96. Universite du Quebec a Chicoutimi. Pichette A, Legault J, Gauthier C. Bidesmosidic betulin and betulinic acid derivatives and uses thereof as antitumor agents. WO2010028487A1; 2010
97. Gauthier C, Legault J, Lebrun M, et al. Glycosidation of lupane-type triterpenoids as potent in vitro cytotoxic agents. Bioorg Med Chem 2006;14:6713-25
98. Universite Du Quebec. Pichette A, Legault J, Gauthier C. Synthesis of triterpene derivatives as antitumor or anti-inflammatory agents. CA2586614A1; 2008
99. Gauthier C, Legault J, Rondeau S, et al. Synthesis of betulinic acid acyl glucuronide for application in anticancer prodrug monotherapy. Tetrahedron Lett 2009;50:988-91
100. Gonzalez P, Mader I, Tchoghandjian A, et al. Impairment of lysosomal integrity by B10, a glycosylated derivative of betulinic acid, leads to lysosomal cell death and converts autophagy into a detrimental process. Cell Death Differ 2012;19:1337-46
101. Wisconsin Alumni Research Foundation. Goff RD, Thorson JS. Enhanced neoglycosides through neo-glycosylation and methods of use thereof. WO2010080863A1; 2010
102. Kim JY, Koo HM, Kim DSHL. Development of C-20 modified betulinic acid derivatives as antitumor agents. Bioorg Med Chem Lett 2001;11:2405-8
103. Rajendran P, Jaggi M, Singh MK, et al. Pharmacological evaluation of C-3 modified betulinic acid derivatives with potent anticancer activity. Invest New Drugs 2008;26:25-34
104. Advanced Life Sciences, Inc. Koohang A, Mar AA, Szotek E, et al. Lupane-type triterpenoids modified at 30-position and analogs thereof. WO2009020732A1; 2009
105. Qian KD, Kim SY, Hung HY, et al. New betulinic acid derivatives as potent proteasome inhibitors. Bioorg Med Chem Lett 2011;21:5944-7
106. Willmann M, Wacheck V, Buckley J, et al. Characterization of NVX-207, a novel betulinic acid-derived anti-cancer compound. Eur J Clin Invest 2009;39:384-94
107. Novelix Pharmaceuticals, Inc. Jansen B. Compositions and methods using betulinic acid derivative NVX-207 and related compounds for treatment of inflammation and hyperkeratotic lesions. WO2009155070A2; 2009
108. Emmerich D, Vanchanagiri K, Baratto LC, et al. Synthesis and studies of anticancer properties of lupane-type triterpenoid derivatives containing a cisplatin fragment. Eur J Med Chem 2014;75:460-6
109. Barycza B, Pawlak A, Poradowski D, et al. Synthesis and cytotoxic activity of betulin and betulinic acid esters with terpenic acids. Przem Chem 2013;92:806-12
110. Majeed R, Sangwan PL, Chinthakindi PK, et al. Synthesis of 3-O-propargylated betulinic acid and its 1, 2, 3-triazoles as potential apoptotic agents. Eur J Med Chem 2013;63:782-92
111. Tubek B, Mitula P, Niezgoda N, et al. Synthesis and cytotoxic activity of new betulin and betulinic acid esters with conjugated linoleic acid (CLA). Nat Prod Commun 2013;8:435-8
112. Yasin Y, Basri M, Ahmad F. Cytotoxic activity of betulinic acid derivatives synthesized using enzymes. J Chem Chem Eng 2010;4:17-23
113. Ahmad FBH, Peter CNL, Abdul Rahman MB, et al. Lipase catalyzed synthesis of anticancer compound: 3b-(3-methylphthalyl)-lup-20 (29)-ene-28-oic. Asian J Chem 2012;24:4875-7
114. Urban M, Vlk M, Dzubak P, et al. Cytotoxic heterocyclic triterpenoids derived from betulin and betulinic acid. Bioorg Med Chem 2012;20:3666-74
115. Sequoia Sciences, Inc. Eldridge GR, Buckle RN, Ellis M, et al. Preparation of heterocyclic-fused triterpenes as inhibitors of bacterial biofilms and related methods. US8324264B1. 2012
116. Santos RC, Salvador JAR, Marin S, et al. Novel semisynthetic derivatives of betulin and betulinic acid with cytotoxic activity. Bioorg Med Chem 2009;17:6241-50
117. Mar AA, Szotek EL, Koohang A, et al. Synthesis, proapoptotic screening, and structure-activity relationships of novel aza-lupane triterpenoids. Bioorg Med Chem Lett 2010;20:5389-93
118. Holy J, Kolomitsyna O, Krasutsky D, et al. Dimethylaminopyridine derivatives of lupane triterpenoids are potent disruptors of mitochondrial structure and function. Bioorg Med Chem 2010;18:6080-8
119. Myriad Genetics, Inc. Yager K, Kim IC, Saunders M, et al. Preparation of betulinic acid derivatives for use in antiviral and anticancer pharmaceutical compositions. WO2008127364A2; 2008
120. Kouzi SA, Chatterjee P, Pezzuto JM, et al. Microbial transformations of the antimelanoma agent betulinic acid. J Nat Prod 2000;63:1653-7
121. Drag-Zalesinska M, Kulbacka J, Saczko J, et al. Esters of betulin and betulinic acid with amino acids have improved water solubility and are selectively cytotoxic toward cancer cells. Bioorg Med Chem Lett 2009;19:4814-17
122. Manciula D, Roba C, Oprean I, Misca-Barbu R. Synthesis of betulinic acid dipeptide derivatives with potential biological activity. Rev Chim 2013;64:1265-9
123. Lan P, Wang J, Zhang DM, et al. Synthesis and antiproliferative evaluation of 23-hydroxybetulinic acid derivatives. Eur J Med Chem 2011;46:2490-502
124. Bi Y, Xu JY, Sun F, et al. Synthesis and antitumor activity of 17-carboxylic acid modified amide derivatives of 23-hydroxy betulinic acid. Rec Nat Prod 2013;7:254-65
125. Bi Y, Xu J, Sun F, et al. Synthesis and biological activity of 23-hydroxybetulinic acid C-28 ester derivatives as antitumor agent candidates. Molecules 2012;17:8832-41
126. Ding W, Sun M, Luo S, et al. A 3D QSAR study of betulinic acid derivatives as anti-tumor agents using topomer CoMFA: model building studies and experimental verification. Molecules 2013;18:10228-41
127. Safe SH, Prather PL, Brents LK, et al. Unifying mechanisms of action of the anticancer activities of triterpenoids and synthetic analogs. Anticancer Agents Med Chem 2012;12:1211-20
128. Giniyatullina GV, Kazakova OB, Medvedeva NI, et al. Synthesis of aminopropylamino derivatives of betulinic and oleanolic acids. Russ J Bioorg Chem 2013;39:329-37
129. Federal'noe Agentstvo po Obrazovaniyu GOU VPO "NGU", Russia; Uchrezhdenie RAN NIOKh im. N. N. Vorozhtsova SO RAN. Pokrovskii AG, Pokrovskii MA, Mainagashev IY, et al. N-ethylpiperazinyl amide of betulinic acid as triterpenic antitumor agent. RU2445317C1; 2012
130. Csuk R, Sczepek R, Siewert B, et al. Cytotoxic betulin-derived hydroxypropargylamines trigger apoptosis. Bioorg Med Chem 2013;21:425-35
131. Sanchez-Munoz S, Gomez-Ruiz S, Perez-Quintanilla D, et al. Preliminary study of the anticancer applications of mesoporous materials functionalized with the natural product betulinic acid. ChemMedChem 2012;7:670-9